Pulmonary Vascular Disease
Patients with pulmonary vascular disease may benefit from restoration of normal blood gases and alveolar gas composition, as alveolar hypoxia, arterial hypercarbia, and acidosis all increase pulmonary vascular tone. the pulmonary vascular disease carries some risks. Right atrial pressure, pulmonary arterial pressure, pulmonary capillary wedge pressure, systemic blood pressure, and mixed venous saturation should be routinely assessed. Cardiac output is determined by thermodilution or estimated with the modified Fick technique, but measurement rather than estimation of oxygen consumption is recommended. Pulmonary vascular resistance, in Woods units times body surface area, is calculated as mean pulmonary arterial pressure minus pulmonary capillary wedge pressure or left atrial pressure divided by cardiac output. Testing with a short-acting vasodilator allows detection of the remaining potential of reactivity of small pulmonary arteries and arterioles or demonstrates fixed resistance.
Related Conference of Pulmonary Vascular Disease
15th International Conference on Pulmonary & Respiratory Medicine
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Pulmonary Vascular Disease Conference Speakers
Recommended Sessions
- Advances in Respiratory Medicine
- Critical Care
- Developmental disorders
- Diffuse Lung Disease
- Environmental &Occupational Lung Disease
- Genetics of Lung Disorders
- Lung Anatomy &Development
- Lung Disease
- Lung Infection
- Mediastinal Disease
- Neoplasms
- Pleural Disease
- Pulmonary Nuclear Medicine
- Pulmonary rehabilitation
- Pulmonary Vascular Disease
Related Journals
Are you interested in
- Advancements in Pulmonary Diagnostics - Respiratory 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Cardio Pulmonary Disorders - Respiratory 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic Obstructive Pulmonary Disease - Respiratory 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and Asthma - Respiratory 2024 (France)
- COVID-19 and Respiratory System - Respiratory 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Idiopathic Pulmonary Fibrosis - Respiratory 2024 (France)
- Interstitial Lung Disease - Respiratory 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung Cancer - Respiratory 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung Transplantation - Respiratory 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Obstructive Sleep Apnea - Respiratory 2024 (France)
- Occupational Lung Diseases - Respiratory 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pneumonia - Respiratory 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary diseases: Treatment, Diagnosis and therapies - Respiratory 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary Hypertension - Respiratory 2024 (France)
- Pulmonary Rehabilitation - Respiratory 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Tuberculosis - Respiratory 2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)